| 心力衰竭:预防和治疗缺一不可 |
| |
| 引用本文： | 徐芬,周洲. 心力衰竭:预防和治疗缺一不可[J]. 协和医学杂志, 2022, 13(6): 953-957. DOI: 10.12290/xhyxzz.2022-0440 |
| |
| 作者姓名： | 徐芬 周洲 |
| |
| 作者单位： | 国家心血管病中心 中国医学科学院阜外医院实验诊断中心，北京 100037 |
| |
| 摘 要： | 美国心脏协会、美国心脏病学会和美国心力衰竭协会联合发布了《2022年AHA/ACC/HFSA心力衰竭管理指南》。该指南倡导心力衰竭防治并重，强调基于利钠肽筛查的一级预防对A期(心力衰竭风险期)或B期(心力衰竭前期)患者至关重要; 推荐C期(心力衰竭期)患者应接受多学科团队管理，尽早使用包括钠-葡萄糖协同转运蛋白2抑制剂的“基础四联疗法”; 并推荐将希望延长生存期的D期(心力衰竭晚期)患者及时转诊至心力衰竭专科团队，以评估晚期心力衰竭治疗的适用性。
|
| 关 键 词： | 心力衰竭 预防 治疗 利钠肽 钠-葡萄糖协同转运蛋白2抑制剂 |
| 收稿时间： | 2022-08-10 |
Heart Failure: Prevention and Treatment are Indispensable |
| |
| Affiliation: | Center of Laboratory Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing 100037, China |
| |
| Abstract: | Recently, 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure has been published. It advocates to pay equal attention to the prevention and treatment of heart failure; and emphasizes that primary prevention based on natriuretic peptides screening is essential for patients at risk for heart failure or with pre-heart failure. Furthermore, it recommends that patients with symptomatic heart failure should receive care from a multidisciplinary team to facilitate the implementation of "basic quadruple therapy" including sodium glucose cotransporter 2 inhibitors; and that patients with advanced heart failure who wish to prolong their survival should be timely referral for heart failure specialty care and assess suitability for advanced heart failure therapies. |
| |
| Keywords: | |
|
| 点击此处可从《协和医学杂志》浏览原始摘要信息 |
|
点击此处可从《协和医学杂志》下载免费的PDF全文 |
